Testing BCD-261 for moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ulcerative colitis for at least 3 months, and it affects the colon beyond the rectum (at least 15 cm from the anal opening).
- Your disease is moderate to severe, with a combined score (including stool frequency, rectal bleeding, and endoscopy findings) between 4 and 9.
- You have tried at least one standard treatment (like steroids, immunosuppressants, or biologic drugs) and it didn't work well enough, or you became dependent on steroids.
- You are not currently taking certain other medications, or if you are, you can stop them for a specific period before starting the trial.
- You do not have a history of Crohn's disease, certain other bowel conditions, or severe complications like colon perforation or dysplasia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational pill for people with moderate-to-severe ulcerative colitis that has not improved with standard treatments. The goal is to see if the pill can reduce symptoms like bloody stools and frequent bowel movements.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests an investigational drug called MB-001 for people with moderate to severe ulcerative colitis who have already tried standard treatments without success. It aims to see if the drug is safe and helps control inflammation.
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.